APOPTOSIS AND %S AS PROGNOSTIC FACTORS FOR COLON CANCER
APOPTOSIS AND %S AS PROGNOSTIC FACTORS FOR COLON CANCER
批准号:
2691257
负责人:
Thomas E. Witzig
金额:
$14.15万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-07-01 至 2000-06-30
关键词:
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The growth of a colon cancer is determined by the rates of malignant
cell proliferation and natural apoptosis. Because of molecular genetic
changes in the cancer cell both of these processes can be disrupted and
lead to tumor growth. We hypothesize that the rate of colon cancer cell
apoptosis is an important determinant of net cancer cell growth and that
a measure of the percent cells in apoptosis will provide additional
prognostic information to the cell proliferation rate. The overall
goals of this proposal are to measure the rates of basal apoptosis and
cell proliferation on specimens of colon adenocarcinomas and relate
these measurements to prognosis and the molecular genetic abnormalities
determined on the same tumor sample. Paraffin-embedded tissue from
patients that participated in randomized, controlled NCCTG clinical
trials which now have adequate follow-up data to correlate these
measurements to colon cancer recurrence and survival. Cell
proliferation and DNA ploidy will be measured using state-of-the-art
flow cytometry hardware and software. Apoptosis will be measured with
a TUNEL technique. We propose to utilize the cell proliferation
(percent S and percent G2M phases) and percent apoptosis measurements
to develop a formula - the colon cancer growth index (CCGI) - that
better predicts prognosis. The second hypothesis to be tested is that
the alterations of cancer cell proliferation and apoptosis are the
consequences of genetic abnormalities and that these genetic
abnormalities will differentially affect proliferation and apoptosis.
This study offers the unique opportunity to study the cell proliferation
and apoptosis rates of colon cancers that have already been studied for
molecular abnormalities by Dr. Steven Thibodeau in a previous study
(NCCTG 93-46-55). By performing these assays on clinical material, we
aim to translate these findings into prognostic tools that can be used
in the clinic to formulate new treatment strategies based on the
knowledge of apoptosis and cell proliferation of colon cancers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
P2 - Signal Transduction Inhibitor Therapy for Lymphoma
-
批准号:8076889
-
项目类别:
-
资助金额:$29.73万
-
财政年份:2010
-
负责人:Thomas E. Witzig
-
依托单位:
Signal transduction inhibitor therapy for Lymphoma
-
批准号:8101349
-
项目类别:
-
资助金额:$32.58万
-
财政年份:2007
-
负责人:Thomas E. Witzig
-
依托单位:
Signal Transduction Inhibitor Therapy for Lymphoma
-
批准号:7254591
-
项目类别:
-
资助金额:$32.03万
-
财政年份:2007
-
负责人:Thomas E. Witzig
-
依托单位:
Signal transduction inhibitor therapy for Lymphoma
-
批准号:7498465
-
项目类别:
-
资助金额:$33.05万
-
财政年份:2007
-
负责人:Thomas E. Witzig
-
依托单位:
Signal transduction inhibitor therapy for Lymphoma
-
批准号:7676766
-
项目类别:
-
资助金额:$33.66万
-
财政年份:2007
-
负责人:Thomas E. Witzig
-
依托单位:
Signal transduction inhibitor therapy for Lymphoma
-
批准号:7249113
-
项目类别:
-
资助金额:$32.88万
-
财政年份:2007
-
负责人:Thomas E. Witzig
-
依托单位:
Signal transduction inhibitor therapy for Lymphoma
-
批准号:7901404
-
项目类别:
-
资助金额:$33.95万
-
财政年份:2007
-
负责人:Thomas E. Witzig
-
依托单位:
PI3K Pathway Inhibitors for Mantle Cell Lymphoma
-
批准号:7140144
-
项目类别:
-
资助金额:$23.95万
-
财政年份:2005
-
负责人:Thomas E. Witzig
-
依托单位:
PI3K Pathway Inhibitors for Mantle Cell Lymphoma
-
批准号:6998325
-
项目类别:
-
资助金额:$25.64万
-
财政年份:2005
-
负责人:Thomas E. Witzig
-
依托单位:
CHARACTERIZATION AND GROWTH OF CLONALLY RELATED MYELOMA CELL
-
批准号:6563836
-
项目类别:
-
资助金额:$22.84万
-
财政年份:2002
-
负责人:Thomas E. Witzig
-
依托单位:
HEMATOLOGY
-
批准号:6665606
-
项目类别:
-
资助金额:$7.89万
-
财政年份:2002
-
负责人:Thomas E. Witzig
-
依托单位:
HEMATOLOGY
-
批准号:6563774
-
项目类别:
-
资助金额:$7.89万
-
财政年份:2002
-
负责人:Thomas E. Witzig
-
依托单位:
Radioimmunotherapy for Lymphoma
-
批准号:6514710
-
项目类别:
-
资助金额:$25.17万
-
财政年份:2001
-
负责人:Thomas E. Witzig
-
依托单位:
Radioimmunotherapy for Lymphoma
-
批准号:6340056
-
项目类别:
-
资助金额:$25.3万
-
财政年份:2001
-
负责人:Thomas E. Witzig
-
依托单位:
APOPTOSIS AND %S AS PROGNOSTIC FACTORS FOR COLON CANCER
-
批准号:2896670
-
项目类别:
-
资助金额:$14.15万
-
财政年份:1998
-
负责人:Thomas E. Witzig
-
依托单位:
Signal Transduction Inhibitor Therapy for Lymphoma
-
批准号:7655530
-
项目类别:
-
资助金额:$30.99万
-
财政年份:--
-
负责人:Thomas E. Witzig
-
依托单位:
Signal Transduction Inhibitor Therapy for Lymphoma
-
批准号:7878111
-
项目类别:
-
资助金额:$29.93万
-
财政年份:--
-
负责人:Thomas E. Witzig
-
依托单位:
P2 - Signal Transduction Inhibitor Therapy for Lymphoma
-
批准号:8302444
-
项目类别:
-
资助金额:$28.18万
-
财政年份:--
-
负责人:Thomas E. Witzig
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: